MCID: PRS042
MIFTS: 42

Prostate Disease

Categories: Endocrine diseases, Nephrological diseases, Reproductive diseases

Aliases & Classifications for Prostate Disease

Summaries for Prostate Disease

MedlinePlus : 43 The prostate is a gland in men. It helps make semen, the fluid that contains sperm. The prostate surrounds the tube that carries urine away from the bladder and out of the body. A young man's prostate is about the size of a walnut. It slowly grows larger with age. If it gets too large, it can cause problems. This is very common after age 50. The older men get, the more likely they are to have prostate trouble. Some common problems are Prostatitis - inflammation, usually caused by bacteria Enlarged prostate (BPH), or benign prostatic hyperplasia - a common problem in older men which may cause dribbling after urination or a need to go often, especially at night Prostate cancer - a common cancer that responds best to treatment when detected early NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Prostate Disease, also known as prostatic diseases, is related to prostatic hyperplasia, benign and prostatic hypertrophy, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Prostate Disease is PCA3 (Prostate Cancer Associated 3). The drugs Iodine and Povidone have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and testes.

Wikipedia : 76 The prostate (from Ancient Greek �?ρο�?�?ά�?η�?, prostates, literally "one who stands before",... more...

Related Diseases for Prostate Disease

Diseases related to Prostate Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Related Disease Score Top Affiliating Genes
1 prostatic hyperplasia, benign 30.1 AR CDKN2B-AS1 FOLH1 KLK3 SERPINA3
2 prostatic hypertrophy 29.6 AR KLK3
3 prostate cancer 29.5 AR CBR3-AS1 CDKN2B-AS1 CTBP1-AS FOLH1 GAS5
4 prostatitis 10.5
5 nodular prostate 10.3 AR FOLH1 KLK3
6 prostate small cell carcinoma 10.3 FOLH1 KLK3
7 suppression of tumorigenicity 12 10.3 AR FOLH1 KLK3
8 male reproductive organ cancer 10.3 AR FOLH1 KLK3 PCA3
9 male reproductive system disease 10.3 AR FOLH1 KLK3 PCA3
10 reproductive system disease 10.3 AR FOLH1 KLK3 PCA3
11 villous adenoma 10.3 FOLH1 KLK3
12 undifferentiated embryonal sarcoma of the liver 10.3 MALAT1 SERPINA3
13 embryonal sarcoma 10.3 MALAT1 SERPINA3
14 vulva squamous cell carcinoma 10.3 MALAT1 MEG3
15 testicular germ cell cancer 10.3 AR MEG3
16 gastric cardia adenocarcinoma 10.3 H19 MEG3
17 androgenic alopecia 10.2 AR KLK3
18 malignant glioma 10.2 CDKN2B-AS1 GAS5 PCGEM1 PRNCR1
19 breast cyst 10.2 KLK3 SERPINA3
20 pituitary adenoma 10.2 H19 MALAT1 MEG3
21 laryngeal squamous cell carcinoma 10.2 CDKN2B-AS1 H19 MALAT1
22 withdrawal disorder 10.2 AR KLK3
23 ovarian epithelial cancer 10.2 H19 MALAT1 MEG3 PCA3
24 bladder urothelial carcinoma 10.2 AR GAS5 KLK3 MALAT1 MEG3
25 thyroid cancer 10.2 CDKN2B-AS1 GAS5 H19 MALAT1
26 thyroid cancer, nonmedullary, 1 10.2 GAS5 H19 MALAT1 MEG3
27 osteoarthritis 10.2 GAS5 H19 MEG3 PCGEM1
28 kidney cancer 10.2 GAS5 H19 MALAT1 MEG3
29 oral squamous cell carcinoma 10.2 H19 MALAT1 MEG3
30 gallbladder cancer 10.2 CDKN2B-AS1 H19 MALAT1 MEG3
31 wilms tumor 1 10.2 AR H19 IGF2-AS MEG3
32 coronary heart disease 1 10.2 CDKN2B-AS1 GAS5 H19 IGF2-AS
33 myeloma, multiple 10.1 GAS5 H19 MALAT1 MEG3 PCAT1
34 lung cancer susceptibility 3 10.1 GAS5 H19 MALAT1 MEG3
35 squamous cell carcinoma 10.1 CBR3-AS1 CDKN2B-AS1 H19 MALAT1 PCAT1
36 nasopharyngeal carcinoma 10.1 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
37 renal cell carcinoma, nonpapillary 10.1 GAS5 H19 LINC00963 MALAT1 PTENP1
38 cystitis cystica 10.1 AR KLK3
39 melanoma 10.1 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
40 endometrial cancer 10.1 AR GAS5 H19 MEG3 PTENP1
41 osteogenic sarcoma 10.1 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
42 glioma 10.1 CBR3-AS1 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
43 esophageal cancer 10.1 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
44 glioblastoma 10.1 GAS5 H19 LINC00963 MALAT1 MEG3 PCAT1
45 bladder cancer 10.0 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
46 cervical cancer 10.0 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
47 pancreatic cancer 10.0 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
48 adamantinoma of long bones 10.0 CDKN2B-AS1 GAS5 H19 KLK3 MALAT1 MEG3
49 lung cancer 9.9 CDKN2B-AS1 GAS5 H19 IGF2-AS MALAT1 MEG3
50 gastric cancer 9.9 CBR3-AS1 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3

Comorbidity relations with Prostate Disease via Phenotypic Disease Network (PDN):


Prostate Cancer Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Prostate Disease:



Diseases related to Prostate Disease

Symptoms & Phenotypes for Prostate Disease

UMLS symptoms related to Prostate Disease:


tremor, angina pectoris, equilibration disorder, prostatism

Drugs & Therapeutics for Prostate Disease

Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 847)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
2
Povidone Approved Phase 4 9003-39-8
3
Povidone-iodine Approved Phase 4,Not Applicable 25655-41-8
4
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106133-20-4 129211
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
6
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474
7
Saw palmetto Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 164656-23-9 6918296 152945
9
Finasteride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98319-26-7 57363
10
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702
11
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
12
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 65807-02-5 47725 5311128
13
Doxazosin Approved Phase 4,Phase 3,Phase 2,Not Applicable 74191-85-8 3157
14
Alfuzosin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 81403-80-7 2092
15
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
16
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-22-0 6013
17
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171596-29-5 110635
18
Testosterone enanthate Approved Phase 4,Phase 2,Phase 1,Not Applicable 315-37-7 9416
19
Methyltestosterone Approved Phase 4,Phase 2,Phase 1,Not Applicable 58-18-4 6010
20
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 5949-44-0
21
Histamine Approved, Investigational Phase 4,Phase 2,Early Phase 1 51-45-6, 75614-87-8 774
22
Lenograstim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
23
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
24
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1 2921-57-5
25
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
26
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 302-25-0
27
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114977-28-5 148124
28
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
29
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53714-56-0 657181 3911
30
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90357-06-5 2375 56069
31
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
32
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
33 tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
34
Pasireotide Approved Phase 4,Phase 1,Phase 2 396091-73-9 9941444
35
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51110-01-1, 38916-34-6 53481605
36
Flutamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13311-84-7 3397
37
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 615258-40-7
38
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 169590-42-5 2662
39
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
40
Terazosin Approved Phase 4,Not Applicable 63590-64-7 5401
41
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
42
Silodosin Approved Phase 4,Phase 3,Phase 2 160970-54-7
43
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
44
Dihydrotachysterol Approved Phase 4,Phase 2 67-96-9 5281010 5311071
45
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
46
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
47
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
48
Midazolam Approved, Illicit Phase 4,Phase 1,Not Applicable 59467-70-8 4192
49
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
50
Promethazine Approved, Investigational Phase 4,Phase 2,Phase 1 60-87-7 4927

Interventional clinical trials:

(show top 50) (show all 4127)
# Name Status NCT ID Phase Drugs
1 A Prospective Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy Unknown status NCT02245334 Phase 4 Povidone-Iodine
2 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Unknown status NCT02034604 Phase 4 Naftofidil;Tamsulosin
3 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLight Laser Photoselective Vaporization of the Prostate Unknown status NCT02749604 Phase 4
4 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
5 Low Dose Bupivacaine Spinal for Trans Uretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
6 Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) Unknown status NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
7 A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia Unknown status NCT01218672 Phase 4
8 Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
9 A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart Unknown status NCT00690950 Phase 4 Dutasteride
10 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
11 Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients Unknown status NCT02006303 Phase 4
12 Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
13 Metformin And Longevity Unknown status NCT02511665 Phase 4 Metformin;Placebo
14 Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Unknown status NCT01379742 Phase 4
15 Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada Unknown status NCT00573586 Phase 4
16 FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
17 Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
18 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
19 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
20 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
21 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
22 Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
23 Treatment of Chronic Bacterial Prostatitis Completed NCT02130713 Phase 4 Third generation fluoroquinolone
24 Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement Completed NCT00648323 Phase 4 Doxazosin mysylate GITS
25 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
26 A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy Completed NCT02423759 Phase 4 ciprofloxacin;ciprofloxacin and gentamycine;culture based chemoprophylaxis
27 FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
28 Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
29 Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
30 KTP Green Light Prostatectomy Compared With Open Prostatectomy Completed NCT02072499 Phase 4
31 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem
32 Prospective Sexual Function Study for BPH Subjects Completed NCT01777269 Phase 4 Dutasteride plus tamsulosin;Placebo
33 Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia Completed NCT01757769 Phase 4 Silodosin
34 Addition of Lidocaine to Levobupivacaine Reduces Intrathecal Block Duration Completed NCT01675895 Phase 4 Levobupivacaine lidocaine spinal anesthesia;levobupivacaine Spinal anesthesia
35 Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) Completed NCT01604811 Phase 4 Permixon® 160 mg;Tamsulosine Arrow LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine Arrow LP
36 Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
37 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
38 Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement Completed NCT01294592 Phase 4 Dutasteride plus tamsulosin;tamsulosin
39 Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) Completed NCT01259531 Phase 4 Silodosin
40 Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate Completed NCT00880672 Phase 4 dutasteride
41 Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Completed NCT00701779 Phase 4 Tamsulosin
42 Once Daily Given Alfuzosin in the Treatment of BPH Completed NCT00637715 Phase 4 Alfuzosin
43 SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00486785 Phase 4 Alfuzosin
44 A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization Completed NCT00465101 Phase 4
45 Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study Completed NCT00427882 Phase 4 ALFUZOSIN
46 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00401661 Phase 4 Alfuzosin
47 A Prospective Evaluation of the GreenLight Model 120 Laser Completed NCT00364585 Phase 4
48 ALF-ONE : ALFuzosin ONcE Daily Completed NCT00280605 Phase 4 Alfuzosin
49 Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP) Completed NCT00199550 Phase 4
50 Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels Completed NCT00062790 Phase 4 Dutasteride

Search NIH Clinical Center for Prostate Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: prostatic diseases

Genetic Tests for Prostate Disease

Anatomical Context for Prostate Disease

MalaCards organs/tissues related to Prostate Disease:

41
Prostate, Kidney, Testes, Endothelial, Heart, Ovary, Pancreas

Publications for Prostate Disease

Articles related to Prostate Disease:

(show top 50) (show all 230)
# Title Authors Year
1
Setting up a service for men with benign prostate disease. ( 29561636 )
2018
2
Canine Prostate Disease. ( 29933768 )
2018
3
Association between male pattern baldness and prostate disease: A meta-analysis. ( 29054497 )
2018
4
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. ( 29335762 )
2018
5
Prostate cancer and prostatic diseases Best of China, 2018. ( 30518869 )
2018
6
20 years-A retrospective of prostate cancer and prostatic diseases. ( 29259294 )
2018
7
CPSE determination and detection of canine prostatic diseases: The importance of a specific diagnosis. ( 29956380 )
2018
8
Re: Evolution of Primary Care Referrals to Urology. Impact of a Protocol on Prostate Disease and Continuing Education. ( 29144897 )
2017
9
Dynamic instrumented palpation - a new method for soft tissue quality assessment: application to prostate disease diagnosis. ( 28965477 )
2017
10
Over-Expression of Activin-I^C Is Associated with Murine and Human Prostate Disease. ( 28116672 )
2017
11
Fatigue, depression, and quality of life in patients with prostatic diseases. ( 28461987 )
2017
12
Simultaneous Detection of Oral Pathogens in Subgingival Plaque and Prostatic Fluid of Men With Periodontal and Prostatic Diseases. ( 28548883 )
2017
13
Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases. ( 28699177 )
2017
14
Knowledge, attitudes and screening practices regarding prostatic diseases among men older than 40 years: a population-based study in Southwest Nigeria. ( 28904679 )
2017
15
Oxidative stress and prostatic diseases. ( 29181163 )
2017
16
Erratum: Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. ( 27436144 )
2016
17
Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. ( 27170414 )
2016
18
Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease. ( 27845125 )
2016
19
A retrospective study of canine prostatic diseases from 2002 to 2009 at the Alfort Veterinary College in France. ( 26613854 )
2016
20
Prostatectomy for benign prostate disease: open, laparoscopic and robotic techniques. ( 26497345 )
2015
21
Initial Evaluation of the Safety of Nanoshell-Directed Photothermal Therapy in the Treatment of Prostate Disease. ( 26296672 )
2015
22
Testosterone Replacement Therapy on the Natural History of Prostate Disease. ( 26077355 )
2015
23
Configuration and validation of a novel prostate disease nomogram predicting prostate biopsy outcome: A prospective study correlating clinical indicators among Filipino adult males with elevated PSA level. ( 29264129 )
2015
24
Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases. ( 25323935 )
2015
25
Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. ( 26171936 )
2015
26
Prostatic diseases under focus in a university hospital in Eastern Saudi Arabia. A 15-year experience. ( 26593165 )
2015
27
MALDI MS profiling of post-DRE urine samples highlights the potential of I^-microseminoprotein as a marker for prostatic diseases. ( 24115268 )
2014
28
Lycopene for the prevention and treatment of prostate disease. ( 24531784 )
2014
29
Evolution of primary care referrals to urology. Impact of a protocol on prostate disease and continuing education. ( 25554605 )
2014
30
Nonsteroidal anti-inflammatory drugs and prostatic diseases. ( 24900965 )
2014
31
New and experimental techniques in the treatment of benign prostatic diseases. ( 25782231 )
2014
32
Androgens and prostate disease. ( 24407178 )
2013
33
Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications. ( 23690774 )
2013
34
Effect of microbubble-enhanced ultrasound on prostate permeability: a potential therapeutic method for prostate disease. ( 23414693 )
2013
35
Current status of 5I+-reductase inhibitors in prostate disease management. ( 23614056 )
2013
36
Recent advances in prostate development and links to prostatic diseases. ( 23335485 )
2013
37
Re: Involvement of estrogen receptors in prostatic diseases. ( 23663624 )
2013
38
Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases. ( 23688836 )
2013
39
Clinico-pathological Correlation of Digital Rectal Examination Findings Amongst Nigerian Men with Prostatic Diseases: A Prospective Study of 236 Cases. ( 24027415 )
2013
40
Hospitalization decreases serum prostate-specific antigen values compared with outpatient values in patients with benign prostatic diseases. ( 24044092 )
2013
41
Treatment for prostate disease should be uniform across the UK. ( 27794764 )
2012
42
Patient reported incontinence after radical prostatectomy is more common than expected and not associated with the nerve sparing technique: results from the Center for Prostate Disease Research (CPDR) database. ( 21826727 )
2012
43
Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10a88ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease? ( 22848218 )
2012
44
Prostate disease risk factors among a New Zealand cohort. ( 23363810 )
2012
45
Botulinum toxin A in prostate disease: a venom from bench to bed-side. ( 22409179 )
2012
46
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-I+ and GPER signalling. ( 22233684 )
2012
47
Role of 5α-reductase inhibitors in benign prostatic diseases. ( 22333687 )
2012
48
Involvement of estrogen receptors in prostatic diseases. ( 22375605 )
2012
49
Editorial comment to involvement of estrogen receptors in prostatic diseases. ( 22621219 )
2012
50
Steroid hormone receptors, matrix metalloproteinases, insulin-like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men. ( 22648746 )
2012

Variations for Prostate Disease

Expression for Prostate Disease

Search GEO for disease gene expression data for Prostate Disease.

Pathways for Prostate Disease

GO Terms for Prostate Disease

Biological processes related to Prostate Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of systemic arterial blood pressure GO:0003073 8.62 AR KLK3

Sources for Prostate Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....